To determine the onset of action, safety and toleration of different formulations and doses of UK-369,003 in patients with erectile dysfunction. Patients should have been previously treated with PDE5 inhibitors and have been responders to the drugs. Duration of treatment is 4 weeks.

Condition	Intervention	Phase
Impotence	Drug: UK-369,003	Phase II

Further Study Details: 

Primary Outcomes: The time needed to obtain an erection hard enough to attempt sexual intercourse.
Secondary Outcomes: Proportion of responders based on successful erections; Based on erections hard enough for sexual intercourse; 15, 45 and 60 minutes post dose; Proportion of good responders based on successful erections; International Index of Erectile Function (IIEF): qu
Expected Total Enrollment:  300

Ages Eligible for Study:  18 Years   -   65 Years,  Genders Eligible for Study:  Male

Criteria

Inclusion Criteria:

• Erectile dysfunction as defined by DSM-IV. Patients should have been PDE5 inhibitor respondents

Exclusion Criteria:

• Alpha blockers and Nitrates of any preparation

Please refer to this study by ClinicalTrials.gov identifier  NCT00141349

Pfizer CT.gov Call Center      1-800-718-1021 

Alabama
      Pfizer Investigational Site, Birmingham,  Alabama,  35205,  United States; Completed
      Pfizer Investigational Site, Birmingham,  Alabama,  35215,  United States; Completed
      Pfizer Investigational Site, Birmingham,  Alabama,  35209-5603,  United States; Completed
Arizona
      Pfizer Investigational Site, Mesa,  Arizona,  85201,  United States; Completed
      Pfizer Investigational Site, Mesa,  Arizona,  85213,  United States; Completed
      Pfizer Investigational Site, Tempe,  Arizona,  85282,  United States; Completed
      Pfizer Investigational Site, Mesa,  Arizona,  85206,  United States; Completed
California
      Pfizer Investigational Site, Beverly Hills,  California,  90212,  United States; Completed
      Pfizer Investigational Site, San Bernardino,  California,  92404,  United States; Recruiting
      Pfizer Investigational Site, Torrance,  California,  90505,  United States; Completed
Connecticut
      Pfizer Investigational Site, Waterbury,  Connecticut,  06708,  United States; Completed
Florida
      Pfizer Investigational Site, Aventura,  Florida,  33180,  United States; Recruiting
      Pfizer Investigational Site, Pembroke Pines,  Florida,  33028,  United States; Recruiting
      Pfizer Investigational Site, West Palm Beach,  Florida,  33407,  United States; Completed
      Pfizer Investigational Site, St. Petersburg,  Florida,  33709,  United States; Completed
Indiana
      Pfizer Investigational Site, Fort Wayne,  Indiana,  46825,  United States; Completed
      Pfizer Investigational Site, Evansville,  Indiana,  47714,  United States; Completed
      Pfizer Investigational Site, Jeffersonville,  Indiana,  47130,  United States; Completed
Louisiana
      Pfizer Investigational Site, Metairie,  Louisiana,  70002,  United States; Recruiting
      Pfizer Investigational Site, Metairie,  Louisiana,  70006,  United States; Recruiting
Massachusetts
      Pfizer Investigational Site, Milford,  Massachusetts,  01757,  United States; Recruiting
Missouri
      Pfizer Investigational Site, Kansas City,  Missouri,  64114,  United States; Completed
New Jersey
      Pfizer Investigational Site, New Brunswick,  New Jersey,  08903,  United States; Completed
New York
      Pfizer Investigational Site, New York,  New York,  10016,  United States; Completed
      Pfizer Investigational Site, Albany,  New York,  12206,  United States; Recruiting
      Pfizer Investigational Site, Endwell,  New York,  13760,  United States; Completed
North Carolina
      Pfizer Investigational Site, Winston Salem,  North Carolina,  27103,  United States; Recruiting
      Pfizer Investigational Site, Raleigh,  North Carolina,  27609,  United States; Completed
      Pfizer Investigational Site, Raleigh,  North Carolina,  27609-7216,  United States; Completed
Ohio
      Pfizer Investigational Site, Cleveland,  Ohio,  44122,  United States; Completed
      Pfizer Investigational Site, Cincinnati,  Ohio,  45212,  United States; No longer recruiting
Texas
      Pfizer Investigational Site, Bryan,  Texas,  77802,  United States; Recruiting
      Pfizer Investigational Site, Sugar Land,  Texas,  77478,  United States; Recruiting
Utah
      Pfizer Investigational Site, Salt Lake City,  Utah,  84109,  United States; Completed
      Pfizer Investigational Site, West Jordan,  Utah,  84088,  United States; Completed
Virginia
      Pfizer Investigational Site, Norfolk,  Virginia,  23502,  United States; Recruiting
      Pfizer Investigational Site, Richmond,  Virginia,  23294,  United States; Recruiting
Wisconsin
      Pfizer Investigational Site, Milwaukee,  Wisconsin,  53209,  United States; Completed

Study chairs or principal investigators

Pfizer CT.gov Call Center,  Study Director,  Pfizer   

Study ID Numbers:  A3711029
Last Updated:  August 31, 2005
Record first received:  August 30, 2005
ClinicalTrials.gov Identifier:  NCT00141349
Health Authority: United States: Food and Drug Administration
ClinicalTrials.gov processed this record on 2005-09-06